J&J Voluntarily Recalls Certain OTC Products - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

J&J Voluntarily Recalls Certain OTC Products


ePT--the Electronic Newsletter of Pharmaceutical Technology

In consultation with the US Food and Drug Administration, McNeil Consumer Healthcare, a division of McNeil-PPC, part of Johnson & Johnson (New Brunswick, NJ) is voluntarily recalling certain lots of over-the-counter (OTC) products in the Americas, the United Arab Emirates, and Fiji, according to a J&J press release.

J&J initiated the recall on Jan. 15, 2009, following an investigation of consumer reports of an unusual moldy, musty, or mildewlike odor that, in a small number of cases, was associated with temporary gastrointestinal events such as nausea, stomach pain, vomiting, or diarrhea.

The recalled products include various strengths and dosage forms of Benadryl, Motrin, Rolaids, Simply Sleep, St. Joseph Aspirin, and Tylenol. The full product recall list may be found here.

McNeil Consumer Healthcare determined that the reported uncharacteristic smell is caused by trace amounts of 2,4,6-tribromoanisole (TBA). The company said that this impurity can result from the breakdown of a chemical that is sometimes applied to wood in pallets that transport and store product-packaging materials. “The health effects of this chemical have not been well studied, but no serious events have been documented in the medical literature,” according to the J&J release.

In December 2009, McNeil Consumer Healthcare also recalled all lots of Tylenol Arthritis Pain 100 count with Ez-Open Cap for the same reason. “McNeil Consumer Healthcare has now applied broader criteria to identify and remove all product lots that it believes may have the potential to be affected, even if they have not been the subject of consumer complaints,” said J&J in the release. “In addition to the product recall, McNeil Consumer Healthcare is continuing [its] investigation into this issue and is taking further actions that include ceasing shipment of products produced using materials shipped on these wood pallets and requiring suppliers who ship materials to our plants to discontinue the use of these pallets.”

McNeil Consumer Healthcare will continue to closely monitor and evaluate the situation and consult with FDA. The company advises consumers who purchased product from the lots included in the recall to stop using the product and contact McNeil Consumer Healthcare for instructions on a refund or replacement.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
How does your company apply quality-by-design (QbD) principles to manufacturing processes?
To all processes for both new and legacy products
To all process for new products only
To select process for new products only
To select processes for both new and legacy products
Do not use QbD
To all processes for both new and legacy products
20%
To all process for new products only
13%
To select process for new products only
24%
To select processes for both new and legacy products
20%
Do not use QbD
22%
View Results
UPCOMING CONFERENCES

Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA
July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA
August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA
August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA
August 20-21, 2013
Request Brochure

See All Conferences >>

Eric Langer Outsourcing Outlook Eric LangerOutsourcing's Modest Role as a Cost-Containment Strategy
Patricia Van Arnum Ingredients Insider Patricia Van ArnumIntellectual Property Battles in Solid-State Chemistry
Nathan Jessop Industry Insider Nathan Jessop Campaign Against Counterfeit Drugs Continues
Lynn Torbeck Statistical Solutions Lynn D. TorbeckCompositing Samples and the Risk to Product Quality
 More
Inadequate Access to Medicines Puts EU at Risk
FDA Offers Insight on QbD for Modified-Release Products
Global Biosimilars Market to Reach $2.445 Billion in 2013
Adapting to Change
AstraZeneca and Exco InTouch Collaborate to Augment Current COPD Pathways
FindPharma Custom Search
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here